Surv Biopharma Inc.
- Biotech or pharma, therapeutic R&D
Surv BioPharma is a biotech developing Oncolytic Virus (OV) cancer therapy and is exploring partnering opportunities for our OV pipelines.
Surv. m-CRA-1 has successfully completed Phase II trials in bone tumors in Japan and is preparing for Phase III trials. Surv. m-CRA-2-IC, a drug for prostate and other cancers, is in the pre-clinical stage and GMP batches are being manufactured.
Address
Kagoshima-shiKagoshima-ken
Japan
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}